SK Biopharmaceuticals makes Christopher Gallen CEO
This article was originally published in Scrip
South Korean pharmaceutical company SK Biopharmaceuticals has appointed Dr Christopher Gallen CEO. He will also serve as CEO of the wholly-owned American affiliate SK Life Science. Dr Gallen was most recently executive vie-president of Zalicus, where he led the clinical and commercial development of pain relief treatment Exalgo (hydromorphone). He previously served at Wyeth Research as vice-president and chief of operations, clinical research and development.